Antonio Russo, MD, PhDUniversity of Palermo, Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo, ItalyRafael Rosell, MD, PhD Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Director, Cancer Biology & Precision Medicine Program, Badalona, Barcelona, SpainChristian Rolfo, MD, PhDAntwerp University Hospital, Phase I - Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp, Edegem, Antwerpen, Belgium
Innehållsförteckning
Introduction.- Oncogene Addiction in Solid Tumors.- Pharmacology and Clinical Development of New Molecularly Targeted Agents.- Biomarkers as Prognostic, Predictive and Surrogate Endpoints.- Evaluation of Response in Malignant Tumors Treated with Targeted Agents.- Targeted Therapies for HER2-Positive Breast Cancer.- Role of PARP Inhibitors in Triple Negative Breast Cancer (TNBC).- Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck.- Targeted Therapies for NSCLC.- Targeted Therapies for Gastric Cancer.- Targeted Therapies for Pancreatic Cancer.- Targeted Therapies in Hepatocellular Carcinoma.- Targeted Therapies for Colorectal Cancer.- Targeted Therapy in Gastrointestinal Stromal Tumors.- Targeted Therapies in Kidney Cancer.- Targeted Therapies in Melanoma.- Targeted Therapies for Prostate Cancer.- Targeted Therapies for Bone Metastases.